

Erratum

In the article by Kudo et al., entitled ‘Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update’ [Oncology 2014;87(suppl 1):22–31, DOI: 10.1159/000368142], there are errors throughout the text and figures that need to be corrected.

1. On p. 26, in figure 11, ‘Yamakado et al.’s criteria (>7 tumors, >4 cm)’ should be ‘Yamakado et al.’s criteria’ (>4 tumors, >7 cm)’.
2. On p. 26, in figure 12, ‘>3–4 cm’ should be ‘>3–5 cm’ and ‘Huge (>4 cm)’ should be ‘Huge (>5 cm)’.
3. On p. 26, left column, line 14, ‘>7 HCCs of >4 cm’ should be ‘>4 HCCs of >7 cm’.
4. On p. 26, right column, line 3, ‘Tumors of >4 cm’ should be ‘Tumors of >7 cm’.
5. On p. 26, right column, line 7, ‘>7 HCCs of >4 cm’ should be ‘>4 HCCs of >7 cm’.
6. On p. 26, right column, line 13, ‘4–7 nodules of 3–4 cm in size (fig. 12)’ should be ‘4–7 nodules of 3–5 cm in size (fig. 12)’.
7. On p. 27, in figure 16, ‘AFP \geq 100 ng/ml’ should be ‘AFP >100 ng/ml’.
8. On p. 29, in figures 20 and 21, ‘Other systemic therapy’ should be ‘Radiotherapy’.
9. On p. 29, in figure 22, ‘Q18’ should be ‘Q19’.
10. On p. 31, right column, line 14, ‘HCC >4 cm and >7 nodules’ should be ‘HCC >7 cm and >4 nodules’.

The corrected figures are printed below.




Fig. 11. Question and answers on Yamakado et al.’s [12] criteria.




Fig. 12. Heterogeneity of intermediate-stage HCC. The green fields indicate good responders to TACE and the pink fields poor responders (colors refer to the online version only). RFA = Radio-frequency ablation.




Fig. 16. Question and answers on the tumor marker levels related to TACE failure/refractoriness.




Fig. 20. Question and answers on the treatment strategy after TACE failure/refractoriness in patients with major portal tumor thrombus.




Fig. 21. Question and answers on the treatment strategy after TACE failure/refractoriness in patients with minor portal tumor thrombus.




Fig. 22. Question and answers on the treatment strategy after TACE failure/refractoriness in patients with extrahepatic spread.